73,000 Scientists collaborate over new COVID-19 Data Portal to speed up vaccine development

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our understanding of the virus to help develop treatments and vaccines quicker.

A new website that allows scientists to share difficult-to-find SARS-CoV-2 data from clinical trials, research centres, hospitals and national healthcare systems, has seen thousands of users collaborating to help beat the novel coronavirus.

Unbounded by red tape or paywalls, the new European COVID-19 Data Platform - an open, digital space for researchers to share and upload data sets - has seen more than 73 thousand users to the platform, and 2.6 million requests since its launch on 20th April of this year.

Gathering clinical information, the Data Portal brings together relevant datasets that are very difficult to find, such as raw and assembled viral sequences.

While scientists across the world have worked on COVID-19 as a national imperative, a big challenge for researchers in the fast-moving situation has been the sharing of data and findings in a coordinated way.

But now, thanks to this new platform, thousands of researchers are already sharing free resources to tackle COVID-19 in the context of the European Open Science Cloud initiative (EOSC).

Seeing global research collaborations, the Portal has a wide spread of nations with the majority of its users coming from the UK (12%), the USA (9%), Spain (8%), Italy (8%) and Germany (7%).

Set up by the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) and the European research infrastructure ELIXIR, the platform is supporting life science laboratories across Europe to share and store their research data.

Coordinated

Generating enormous amounts of data from clinical trials, research centres, hospitals and national healthcare systems on the disease, the COVID-19 Data Portal has successfully coordinated the data since the pandemic began spreading in early February 2020.

Project coordinator of EOSC-Life, Niklas Blomberg said: "We are really impressed with the rapid uptake of the portal.

"Already we are seeing the platform play a key role in allowing scientists to understand fundamental questions about the virus. Researchers are sharing knowledge on how the virus mutates when spreading, the basic biology of the virus, how it infects, whether there are any drug targets or intervention points where known drugs can be repurposed, and the human response, for example, the genetic risk factors for the severity of the disease.

"The work in EOSC-Life on Europe-wide solutions for federated access to data that cannot be openly shared - for example, human genomes and disease data, data from clinical trials, access to biobank samples from European biobanks - is directly supporting the portal development. The work provides a blueprint for long-term solutions and potentially helps to prepare us for future outbreaks."

Federation of Data

Blomberg believes this will pave the way for a federated model - a multi-layered federation of data supplying a wide range of publicly-funded services at national, regional and institutional levels.

"The data gathered will result in rich datasets, for example, genetics, proteomics and serology, collected from a large number of COVID-19 patients and these data need to be stored and shared in a secure and GDPR- compliant manner. Thus we need to transition from a centralised model to a federated system with data deposition and access across Europe," said Blomberg.

The success of the Data Portal has many Open Science advocates stressing the need for a federated European data ecosystem.

EMBL Head of IT and EOSC Executive Board Member Rupert Lueck said: "The collective global scientific effort to study the disease, find vaccines and develop cures has been stunning, but would arguably not have been the same behind paywalls.

"The COVID-19 Data Portal has allowed scientists to progress at a phenomenal rate unencumbered by red tape - keeping the focus on science, shortening timelines and showing the importance of open data in well-kept repositories. It proves that accessible and well-curated data can produce rapid responses and high-quality, reproducible science."

Blueprint for the Future

The success of the Data Portal has many seeing this as a first step to creating a wider network of COVID-19 data hubs. Amonida Zadissa, Project Manager at EMBL-EBI said: "Given that a large part of the COVID-19 host data will come directly from clinical care it will be subject to national laws and regulations. Much of this data is unlikely to be consented to leave national jurisdictions.

"Therefore, the rapid response to the COVID-19 pandemic provides a blueprint for European data access in projects such as 1 Million European Genomes and the European Health Research and Innovation Cloud."

You can find the link to submit your COVID-19 data here.

For further information, please visit:
https://www.covid19dataportal.org

Most Popular Now

Observational study identifies drug that improves …

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,0...

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Roche and Regeneron collaborate to significantly i…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Regeneron (NASDAQ: REGN) announced are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...